GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its ...

On Friday, AstraZeneca Plc AZN released positive topline data from Phase 3 OBERON and TITANIA trials of tozorakimab in ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Patients with both chronic obstructive pulmonary disease (COPD) and severe pain are at an almost 40% predicted probability of falling, indicating the potential interaction between the conditions.

Integrated primary care services may offer better outcomes in patients living with severe chronic obstructive pulmonary disease (COPD) without increasing costs. The integrated primary care ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

Noninvasive ventilation is a well-known life-sparing option during acute exacerbations of chronic obstructive pulmonary disease (COPD), but its effectiveness for severe, but stable disease has been ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary hypertension appears in 25% to 30% of patients with COPD. There are no approved therapies for patients ...

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk ...